NCT04153032 Comparative Evaluation of MEBO Ointment and Topical Diltiazem Ointment in the Treatment of Acute Anal Fissure
| NCT ID | NCT04153032 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | American University of Beirut Medical Center |
| Condition | Anal Fissure |
| Study Type | INTERVENTIONAL |
| Enrollment | 183 participants |
| Start Date | 2019-12-01 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 183 participants in total. It began in 2019-12-01 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
No study to date has compared topical DTZ to MEBO ointment in the treatment of anal fissure. Therefore, the present study aims to compare the efficacy and safety of DTZ to MEBO in the treatment of acute anal fissure. The investigators propose to conduct a comparative randomized clinical study. In this study, the investigators will compare patients with acute anal fissure receiving MEBO ointment vs Topical DTZ ointment vs a combination of MEBO and DTZ ointment. Hypothesis: MEBO in combination with DTZ is more effective than DTZ or MEBO alone in the treatment of acute anal fissure.
Eligibility Criteria
Inclusion Criteria: * Subjects must be 18 years and above. * Subjects with 3 months (90 days) or less history of painful anal fissure (AF), prior to screening, where AF-related pain-associated with, or following, defecation is experienced at least twice a week during the symptomatic phase, with pain scores at an average of ≥ 3 on an 11-point NRS (Numerical Rating Scale, range 0-10 where 0 = no pain and 10 = worst pain imaginable). * Subjects with an average of ≥4 on an 11-point NRS during the screening phase for worst anal pain associated with, or following, defecation for the most recent 3 days on which the subject has defecated. * Subjects with evidence of a radial fissure, with induration at the edges, seen on anal examination. * Willing to stop all other concomitant topical preparations applied perianally prior to commencing study treatment, and throughout the study. There will be a "washout" period of at least 2 weeks prior to commencing the study for subjects who were using other concomitant topical preparations applied perianally. * Able to give consent Exclusion Criteria: * Subjects unwilling to be examined for AF. * Subjects who have undergone the following procedures: * Lateral sphincterotomy or anal stretch or other previous surgery involving the anal canal or perianal region (hemorrhoidectomy, anal fistula surgery). * Incision of perianal abcess. * Subjects who have had sub-fissure injection of botulinum toxin within 6 months period prior to screening, or have used glyceryl trinitrate (GTN) ointment for \>1 week in the 4 weeks prior to the screening visit. * Subjects with AF associated with other conditions (drug-induced \[e.g. nicorandil\], trauma, HIV infection, fistula-in-ano, inflammatory bowel disease, perianal sepsis or malignancy). * Subjects with cardiovascular disease * Subjects with known hypersensitivity to DTZ or the ingredients of MEBO (Sesame oil) * Subjects taking medications prohibited by the protocol. * Subjects who have taken experimental agents must have been discontinued at least 8 weeks prior to screening, or for a period equivalent to 5 half-lives (t1/2) of the agents. * Subjects who have the following gastrointestinal disorders: * Inflammatory bowel disease. * Chronic faecal incontinence. * History of radiation therapy to the pelvis. * Fixed anal stenosis/fibrosis. * Subjects with major psychiatric (including drug or alcohol abusers), or haematological illness. (diseases of the vascular system; source: )Subjects with planned elective or other treatment requiring hospitalization, during the study, booked before entry into the study. * Subjects who will be unavailable for the duration of the trial, likely to be noncompliant with the protocol, or who are felt to be unsuitable by the Investigator for any other reason. * Patients who are taking oral therapy for anal fissure will also be excluded from the study.
Contact & Investigator
Eman Sbaity, MD
PRINCIPAL INVESTIGATOR
American University of Beirut Medical Center
Frequently Asked Questions
Who can join the NCT04153032 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Anal Fissure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04153032 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT04153032 currently recruiting?
Yes, NCT04153032 is actively recruiting participants. Contact the research team at es25@aub.edu.lb for enrollment information.
Where is the NCT04153032 trial being conducted?
This trial is being conducted at Beirut, Lebanon.
Who is sponsoring the NCT04153032 clinical trial?
NCT04153032 is sponsored by American University of Beirut Medical Center. The principal investigator is Eman Sbaity, MD at American University of Beirut Medical Center. The trial plans to enroll 183 participants.